SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
EWTX reported Third Quarter 2026 results. The stock moved +3.6% on the print.
EWTXearnings

Earnings reactions, page 7

Edgewise Therapeutics, Inc. (EWTX) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Cash, cash equivalents and marketable securities were $1,743.9 million as of September 30, 2026.
  • Research and development (R&D) expenses were $31.6 million for the third quarter of 2026.
  • General and administrative (G&A) expenses were $14.6 million for the third quarter of 2026.
  • Gain on sevasemten sale was $1.348 billion for the third quarter of 2026.
  • Net income was $1,166.2 million, or $10.71 per basic share and $9.65 per diluted share, for the third quarter of 2026.

Guidance

  • The Company expects to initiate its Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) by year-end 2026.

Notes

The gain on the sevasemten sale reflects the completion of the sale of the sevasemten program and muscular dystrophy business to Servier in July 2026.

Price and volatility reaction

The stock moved +3.6% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -9.1 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release37.532026-11-04
Close after release38.872026-11-05
Realised move+3.6%close to close
30d ATM IV change-9.1 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-04 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →